We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+12.09%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$823M
AUM Growth
-$2.43M
Cap. Flow
-$27.4M
Cap. Flow %
-3.33%
Top 10 Hldgs %
55.08%
Holding
68
New
13
Increased
12
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$14.4M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$13.6M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.6M
4
CORI
Corium International, Inc.
CORI
+$9.81M
5
PETX
Aratana Therapeutics, Inc.
PETX
+$9.16M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$19.9M
2
ADXS
Advaxis Inc
ADXS
+$12.4M
3
MDCO
Medicines Co
MDCO
+$10.5M
4
DRRX
DURECT Corp
DRRX
+$8.93M
5
SPNE
SeaSpine Holdings Corporation Common Stock
SPNE
+$8.63M

Sector Composition

Rank Sector Weight
1 Healthcare 74.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXTR
51
DELISTED
Dextera Surgical Inc.
DXTR
$296K 0.04%
987,520
+388,080
+65% +$196K
SSKN
52
DELISTED
Strata Skin Sciences
SSKN
$162K 0.02%
6,661
-12,567
-65% -$350K
ARCT icon
53
Arcturus Therapeutics
ARCT
$165M
– –
-173,806
Closed -$1.39M
DRRX
54
DELISTED
DURECT Corp
DRRX
– –
-850,623
Closed -$8.93M
DXCM icon
55
DexCom
DXCM
$27.2B
– –
-197,200
Closed -$4.18M
SCYX icon
56
SCYNEXIS
SCYX
$39.3M
– –
-18,466
Closed -$4.08M
VXRT
57
DELISTED
Vaxart
VXRT
– –
-289,021
Closed -$2.07M
AVGR
58
DELISTED
Avinger, Inc. Common Stock
AVGR
– –
-4
Closed -$950K
SPNE
59
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
– –
-1,099,807
Closed -$8.63M
ADXS
60
DELISTED
Advaxis Inc
ADXS
– –
-101,284
Closed -$12.4M
PGNX
61
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-250,000
Closed -$2.36M
GNMX
62
CALL
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-500,000
Closed -$930K
MDCO
63
DELISTED
Medicines Co
MDCO
– –
-215,077
Closed -$10.5M
WINT
64
DELISTED
Windtree Therapeutics Inc
WINT
– –
-777,797
Closed -$887K
OMED
65
CALL
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
– –
-300,000
Closed -$2.76M
BCR
66
DELISTED
CR Bard Inc.
BCR
– –
-27,300
Closed -$6.79M
1 2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Broadfin Capital held 68 positions worth $823M, down 0.29% from $826M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Broadfin Capital withdrew a net $27.4M in Q2 2017, closing 14 positions and reducing 21 holdings. Its most notable exit was Advaxis Inc, an estimated $12.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 77% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in Aerie Pharmaceuticals worth $16.3M.

  • Broadfin Capital's largest Q2 2017 buy was Aerie Pharmaceuticals: 310,000 shares worth $16.3M.
  • Broadfin Capital added most to La Jolla Pharmaceutical Company in Q2 2017, an estimated $13.6M increase.
  • Broadfin Capital's biggest Q2 2017 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $19.9M.
  • Broadfin Capital fully exited Advaxis Inc in Q2 2017, selling an estimated $12.4M.
  • Broadfin Capital's ten largest holdings make up 55% of its $823M portfolio in Q2 2017.
  • Broadfin Capital opened 13 new positions and closed 14 in Q2 2017.
  • Broadfin Capital's portfolio value fell 0.29% quarter-over-quarter to $823M.

Based on Broadfin Capital's 13F filing for Q2 2017, filed 14 Aug 2017.